To Evaluate the Safety and Efficacy of Pregabalin in Patients With Painful Diabetic Peripheral Neuropathy.

Phase 3CompletedNCT00150423

Pfizer384 enrolled

Overview

To evaluate the safety and efficacy of pregabalin in patients with painful diabetic peripheral neuropathy.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

384

Conditions

Diabetic Neuropathy, Painful

Interventions

PregabalinDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Must have met the inclusion criteria for the preceding double-blind BID study in painful diabetic peripheral neuropathy * Must have received pregabalin/placebo under double-blind conditions for a minimum of 3 weeks. Exclusion Criteria: * Patients may not participate if they experienced a serious adverse event during the preceding double-blind BID study which was determined to be related to the study medication.

Outcomes

Primary Outcomes

Safety Efficacy

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.